Pacemakers Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Pacemakers Market size was valued at around USD 6.2 billion in 2023 and is anticipated to grow at a CAGR of around 10% between 2024 and 2032. The rising prevalence of cardiovascular diseases, surging incidence of arrhythmias, technological advancement, the growing ageing population, and supportive initiatives adopted by various governments & public organizations.
A pacemaker is a medical device that generates electrical impulses to regulate the heartbeat when the heart's natural electrical conduction system is not functioning properly, playing a critical role in cardiac rhythm management. Pacemakers help maintain an appropriate and consistent heart rate, ensuring that the heart beats regularly and at a sufficient rate to meet the body's oxygen and blood flow needs.
Report Attribute | Details |
---|---|
Base Year: | 2023 |
Pacemakers Market size in 2023: | USD 6.2 Billion |
Forecast Period: | 2024 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 4.5 |
2023 Value Projection: | USD 9.2 Billion |
Historical Data for: | 2018 to 2023 |
No of Pages: | 96 |
Tables, Charts & Figures: | 329 |
Segments Covered: | Product, Technology, Application, End-use and Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
The high cost of these devices for patients not covered by insurance in the U.S. and patients in other parts of the world along with the cost of implantation procedures. The pacemaker device costs around USD 19,000 – 96,000 or more depending on the type of pacemaker, the location, and the length of stay. The total cost for pacemaker implantation ranges from USD 9,616 to 19,716 with an average cost of USD 14,290. The high cost of the device and procedures remains unaffordable to the low and middle-income patient population in the developing regions.
The onset of the COVID-19 pandemic was an unprecedented event impacting public health and led to an incremental surge in the number of hospitalizations. The COVID-19 pandemic also had a detrimental impact on the medical ecosystem, pushing widespread reallocation of healthcare personnel.
The increasing prevalence of cardiovascular diseases is one of the major factors propelling the pacemakers industry gains and the adoption of cardiovascular devices. According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. The increasing incidence & prevalence of cardiovascular conditions, such as congestive heart failure, arrhythmias, bradycardia, and tachycardia. As per the NCBI article, in 2023, ventricular tachycardia & fibrillation majorly accounts for sudden cardiac death with an estimated rate of 300,000 mortalities every year in the U.S. This accounts for around half of the mortalities associated with cardiac anomalies.
Based on product, the market is segmented as implantable pacemakers and external pacemakers. Implantable pacemakers segment was valued at USD 5.7 billion and is projected to expand at a CAGR of 4.6% during the forecast period to reach a market value of USD 8.5 billion by 2032.
Based on technology, the pacemakers market is segmented as single-chamber pacemakers, dual-chamber pacemakers, and biventricular/CRT pacemakers. The Dual-chamber pacemakers segment garnered around USD 4.8 billion in revenue in 2023.
Based on application, the pacemakers market is segmented as bradycardia, congestive heart failure, arrhythmias, tachycardia, and other applications. Application of pacemakers in arrythmias was valued at USD 1.1 billion in 2023. This is primarily attributable to the growing incidence rate of recurrent arrhythmia due to factors such as sedentary lifestyle disorders and increasing incidence of heart attacks across the globe.
Based on end-use, the pacemakers market is segmented into hospitals & clinics, cardiac care centers, ambulatory, surgical centers, and other end-users. The hospitals & clinics segment is projected to reach more than USD 4.9 billion by 2032. The soaring use of pacemakers in hospital settings delivering rapid and reliable outcomes is estimated to surge the patient preference for these healthcare facilities.
The U.S. dominated the North American pacemakers market is anticipated to expand at a notable pace to reach more than USD 3.1 billion by 2032.
The pacemakers industry is consolidated in nature, with major companies competing to offer superior pacemakers in this business space. Prominent players such as Medtronic plc hold a significant company industry share.
Some of the eminent market participants operating in the pacemakers industry include:
By Product, 2018 - 2032 (USD Million)
By Technology, 2018 - 2032 (USD Million)
By Application, 2018 - 2032 (USD Million)
By End-use, 2018 - 2032 (USD Million)
The above information is provided for the following regions and countries:
The U.S. pacemakers market is anticipated to expand at a notable pace to reach more than USD 3.1 billion by 2032, attributed to the presence of major industry players, an upsurge in the demand for cardiovascular devices, and the growing number of hospital admissions across the country.
Abbott Laboratories, Inc., Boston Scientific Corporation, Medtronic plc, BIOTRONIK SE & Co. KG, Lepu Medical Technology, Shree Pacetronix Ltd., Osypka Medical, MicroPort Scientific Corporation, Medico S.R.L., and Vitatron, among others.
The pacemakers industry was valued at around USD 6.2 billion in 2023 and is estimated to reach over USD 9.2 billion by the end of 2032, owing to the rising prevalence of cardiovascular diseases and surging incidence of arrhythmias.
The dual-chamber pacemakers technology segment garnered around USD 4.8 billion in 2023 and is expected to foresee a healthy growth as increase in number of people suffering from atrioventricular block, who get benefited from using this device.